Provectus Pharmaceuticals, Inc. PVCT,
a development-stage oncology and dermatology biopharmaceutical company,
has received U.S Patent No. 8,530,675 by the United States Patent and
Trademark Office (USPTO), protecting the synthetic process used to
produce the small molecule Rose Bengal, the active pharmaceutical
ingredient (API) in PV-10, the Company's lead oncology drug candidate.
The new patent, entitled, “Process for the Synthesis of
4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5',7'-tetraiodo-3H-spiro[isobenzofuran-1,9'-xanthen]-3-one
(Rose Bengal) and Related Xanthenes,” was originally filed on September
17, 2010. The patent details a new process for the manufacture of Rose
Bengal and related iodinated xanthenes in high purity, and was allowed
in June 2013. The patent covers the process under which pharmaceutical
grade Rose
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in